“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights – all of which have Buy ratings at major firms and are trading under the $10 level. For these five stocks –which include an intriguing biotech play with…
With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of…
Thanks to her bet on disruptive DNA, Bloomberg named ARK Investment Management’s Cathie Wood the best stock picker of 2020. What does Wood believe are going to be the most disruptive sectors going forward, and what specific companies are working on truly disruptive technologies with the potential to change the course of history? For more – including a look at…
“These five top stocks are all on the BofA Securities US 1 list of top picks. They all are very prominent in their respective silos in the financial and health care sectors, and all are great second-quarter ideas for growth investors with a little bit of risk tolerance looking to rotate capital,” says the author of today’s article of the…
When it comes to creating a useful profile for monster growth stocks, the author of today’s article lays out the following criteria: “gangbusters gains, Buy ratings from the Wall Street analyst corps, and considerable upside for the coming year.” With that, he proceeds to highlight three stocks that meet the profile for monster growth, including one that “puts a different…
“Far from a dead company, this may be one of the best held secrets in the biotech landscape,” declares the author of today’s article of the little-followed biotechnology company they highlight: an “antibody discovery company that could have the potential to revolutionize the process for discovering and rapidly advancing new therapies.” For more, CLICK HERE.
Just as certain COVID-19 vaccines may be better suited for certain groups of people, certain COVID-19 vaccine stocks may be better suited for different investing styles. So, of the six leaders or potential leaders in the U.S. COVID-19 vaccine space right now, which may be the best pick for conservative investors and which may be the best pick for aggressive…
The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about…
Among the four biotech stocks that may be worth considering this month highlighted in today’s article is a company focused on developing genetic therapies with the potential to restore, improve and preserve high-acuity physiological hearing for people living with certain forms of disabling hearing loss. For more on this company and the other three biotech stocks featured, CLICK HERE.
“The company highlighted in today’s article “helps its customers to find the exceedingly rare cells/antibodies needed to fight cancer, inflammation etc. Basically, to find the needle in the haystack” – and as it operates in a high-growth and rapidly expanding area of biotech, the author believes that this digital cell biology company is a solid candidate for high-growth/high-risk portfolios. For…